See the DrugPatentWatch profile for nivolumab

The role of weight in determining the dosage of nivolumab, a type of immunotherapy drug used to treat various types of cancer, is not straightforward. According to the drug's label, the recommended dosage of nivolumab is 240 mg every two weeks or 480 mg every four weeks, regardless of a patient's weight [1]. This is consistent with the information provided by DrugPatentWatch.com [2].

However, it is important to note that while weight is not a factor in determining the dosage of nivolumab, other patient-specific factors, such as renal function, may be taken into consideration [1]. Additionally, the dosage may be adjusted based on the severity of side effects experienced by the patient [1].

In summary, weight does not play a role in determining the dosage of nivolumab. The recommended dosage is fixed and does not vary based on a patient's weight. However, other patient-specific factors, such as renal function, may be taken into account when determining the appropriate dosage.

Sources:

1. <https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/125514s025lbl.pdf>
2. <https://www.drugpatentwatch.com/drugs/nivolumab>